目的 探討氨基葡萄糖聯合布洛芬治療髖關節骨關節炎的臨床療效。 方法 2011年9月－2012年1月采用前瞻性隨機對照臨床試驗，將198例輕、中度髖關節骨關節炎患者隨機分入試驗組及對照組。試驗組采用氨基葡萄糖（750 mg， 2次/d口服，療程1個月）聯合布洛芬（0.3 g，2次/d口服，療程2周），對照組則單用布洛芬（0.3 g，2次/d口服，療程2周）；分別于服藥后0、2、4、8及12周時采用加拿大西安大略和麥克瑪斯特大學骨關節炎指數（WOMAC）進行療效評價。并對惡心、嘔吐、皮疹等藥物不良反應進行觀察。 結果 試驗組與對照組WOMAC各項評分從第2周開始較0周明顯下降，而兩組患者間在0周及2周時WOMAC評分無統計學差異：0周總評分（45.3、45.0分，P=0.225），2周總評分（37.3、37.6分，P=0.329）。但對照組WOMAC各項評分從第4周開始逐漸呈現上升趨勢，而試驗組到第12周仍呈現持續性下降趨勢。總不良反應發生率為7.0%，其中試驗組總不良反應發生率為9.5%，但不良反應輕微，未予特殊處理而自行消失。 結論 氨基葡萄糖聯合布洛芬可有效緩解早、中期髖關節骨關節炎各項臨床癥狀，療效確切，不良反應較少，且停藥后仍持續表現出治療效果。而單用布洛芬可短期緩解骨關節炎癥，但停藥后癥狀逐漸復現。
In recent years, reports of domestic robot-assisted total knee arthroplasty have gradually increased. In response to problems that may arise during the perioperative period, West China Hospital of Sichuan University has adopted measures such as the establishment of multidisciplinary team, adequate preoperative evaluation, precise intraoperative operations, and whole process optimization management (incision management, pain management, functional exercise and follow-up management). Combined with the actual clinical situation, a domestic robot-assisted total knee arthroplasty management program during the perioperative period was explored and formulated to promote the recovery of patients. This article introduces the above-mentioned program, and aims to provide a reference for the management optimization of domestic robot-assisted total knee arthroplasty during the perioperative period.